This is the main highlight from the Study on investment in the Biomedical industry in Catalonia: Achievements and future challenges presented on June 12th by CataloniaBio & HealthTech and EY in Barcelona. This will allow Catalan biomedical companies to push forward in the development of drugs and innovative medical technology.
The study also points out that venture capital continues to be the main source of funding for companies that develop products (33%), while service firms tend to opt for private debt (74%). Most investors are from Catalonia (76%), although foreign capital is increasing (from 12% in 2016 to 16% in 2017). Venture capital experts reported positive results for 2017 and improvements beyond the investment figures. Specifically, investors say there are three important consolidated trends: larger rounds of funding, greater participation from international funds and evolving management teams.
The study is available in digital format through the CataloniaBio & HeathTech website.